Big Tech Is About to Report. My Plan: Do Nothing
Reports loom for Microsoft, Alphabet and Amazon, but I see no edge in trying to bet on those outcomes. Here’s what I’ll do instead.
AI Sees Weak Bounce While Anthropic Filing Fails to Resolve Concerns
Chips and the mega caps bounced, but breadth was weak and new lows stayed high.
AI Names Crater, Average Stocks Rise in Dramatic Rotation
The gap is closing, but the opportunity is in new leaders, not broken AI names.
Market Gap Narrows and It’s Time to Put Cash to Work
The AI complex is getting hit on earnings while small caps, biotech, retail and defensive pharma hold up. Here’s what I’m buying.
SpaceX Beats, but the Test Is Whether It Can Build on the Gains
Last quarter’s strong AI beats faded. Will it be different this time? Here’s my plan for SPCX.
Gap Between Market’s 2 Tiers Starts to Close
SpaceX saw beats on both the top and bottom line but is trading flat in front of the conference call.
How I’m Trading SpaceX Earnings as Rotation Gains Traction
Money is moving out of tech ahead of the big reports, and Oscar Health just gave me a reason to add.
The Run-Up to Black Monday in 1987 Looks a Lot Like 2026
While there are some similarities to 1987, there are also some major differences.
The AI Trade Isn’t Over, but the Easy Gains Likely Are
The hot CPI report finally triggered the rotation. Breadth was the best in weeks as money moved toward the laggards.
Amid Rotation, I’m Adding to an Obscure Biotech and a Magnificent 7 Stock
Here’s my plan as AI stocks are sliding while money moves into the names that struggled for months, and biotech is leading the way.